Editing Psychosis (section)

==== Psychedelics ====
A 2024 meta-analysis found an incidence of psychedelic-induced psychosis at 0.002% in population studies, 0.2% in uncontrolled clinical trials, and 0.6% in randomised controlled trials.<ref>{{Cite journal |last1=Sabé |first1=Michel |last2=Sulstarova |first2=Adi |last3=Glangetas |first3=Alban |last4=De Pieri |first4=Marco |last5=Mallet |first5=Luc |last6=Curtis |first6=Logos |last7=Richard-Lepouriel |first7=Héléne |last8=Penzenstadler |first8=Louise |last9=Seragnoli |first9=Federico |last10=Thorens |first10=Gabriel |last11=Zullino |first11=Daniele |last12=Preller |first12=Katrin |last13=Böge |first13=Kerem |last14=Leucht |first14=Stefan |last15=Correll |first15=Christoph U. |date=November 2024 |title=Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies |journal=Molecular Psychiatry |language=en |volume=30 |issue=3 |pages=1223–1255 |doi=10.1038/s41380-024-02800-5 |pmid=39592825 |issn=1476-5578|pmc=11835720 }}</ref> This meta-analysis found that in uncontrolled clinical trials involving only patients with schizophrenia, 3.8% developed prolonged psychotic reactions. A 2024 study found that [[psychedelic]] use was not generally associated with a change in the number of psychotic symptoms.<ref>{{Cite journal |last1=Honk |first1=Ludwig |last2=Stenfors |first2=Cecilia U. D. |last3=Goldberg |first3=Simon B. |last4=Hendricks |first4=Peter S. |last5=Osika |first5=Walter |last6=Dourron |first6=Haley Maria |last7=Lebedev |first7=Alexander |last8=Petrovic |first8=Predrag |last9=Simonsson |first9=Otto |date=2024-04-15 |title=Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom |journal=Journal of Affective Disorders |volume=351 |pages=194–201 |doi=10.1016/j.jad.2024.01.197 |pmid=38280572 |pmc=10922895 |issn=0165-0327}}</ref> This study found that psychedelic use interacted with a family history of bipolar disorder, such that in those with a family history of bipolar disorder, psychedelic use was associated with an increase in the number of psychotic symptoms, while in those with a personal history of psychosis but no family history of psychotic disorders, psychedelic use was associated with a decrease in the number of psychotic symptoms. A 2023 study found an interaction between lifetime psychedelic use and family history of psychosis or bipolar disorder on psychotic symptoms over the past two weeks. Psychotic symptoms were highest among individuals with both a family history of psychosis or bipolar disorder and lifetime psychedelic use, while they were lowest among those with lifetime psychedelic use but no family history of these disorders.<ref>{{Cite journal |last1=Simonsson |first1=Otto |last2=Goldberg |first2=Simon B. |last3=Chambers |first3=Richard |last4=Osika |first4=Walter |last5=Simonsson |first5=Charlotta |last6=Hendricks |first6=Peter S. |date=2023-10-24 |title=Psychedelic use and psychiatric risks |journal=Psychopharmacology |language=en |doi=10.1007/s00213-023-06478-5 |issn=1432-2072 |pmc=11039563 |pmid=37874345}}</ref>